Director-Affiliated Funds Disclose 12.5% Stake in Veradermics Post-IPO
MANE sits 39% above its 52-week low of $32 on light trading volume (0.3× avg).
Summary
Longitude Capital and its managing members, including Director Patrick G. Enright, have disclosed a 12.5% beneficial ownership stake in Veradermics, Inc., primarily through pre-IPO investments and purchases during the recent IPO.
Key Events · Ownership and Investor Activity · MANE
-
Significant Ownership Disclosure
Longitude Capital and its managing members, including Director Patrick G. Enright, reported a 12.5% beneficial ownership stake in Veradermics, Inc.
-
Substantial Investment Value
The disclosed stake is valued at approximately $206.8 million, representing a significant portion of the company's market capitalization.
-
Pre-IPO and IPO Participation
The ownership was primarily established through investments in Series B and Series C preferred stock, which converted to common stock upon the IPO, and additional purchases during the IPO on February 5, 2026.
-
Director Alignment
Patrick G. Enright, a director of Veradermics, is a managing member of the reporting funds, aligning insider interests with the institutional investment.
Analysis · MANE · Life Sciences
This Schedule 13D filing reveals that Longitude Capital, along with its managing members Patrick G. Enright (a director of Veradermics) and Juliet Tammenoms Bakker, collectively hold a substantial 12.5% beneficial ownership in Veradermics, Inc. The stake, valued at approximately $206.8 million based on the current stock price, was accumulated through significant investments in Series B and Series C preferred stock prior to the IPO, which converted to common stock, and additional purchases during the company's initial public offering on February 5, 2026. This disclosure, following other recent 13D filings and insider purchases, highlights strong institutional and insider conviction in the company post-IPO, especially as the stock trades near its 52-week high. The reporting persons have also entered into a 180-day lock-up agreement, indicating a long-term investment horizon.
At the time of this filing, MANE was trading at $44.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $32.00 to $45.78. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.